Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 18/20 | 0.77 |
| ▸ | KDR | P35968 | 2/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.62 |
| ▸ | KIT | P10721 | 1/20 | 0.62 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4472020 | 0.87 | FGFR2 (1.00) | FGFR2KDRPDGFRBKITPDGFRA | |
| SCHEMBL4473682 | 0.87 | FGFR2 (0.84) | FGFR2KDRPDGFRBKITPDGFRA | |
| SCHEMBL7486930 | 0.86 | PDGFRA (0.67) | FGFR2KDRPDGFRA | |
| SCHEMBL4484850 | 0.85 | FGFR2 (1.00) | FGFR2KDRPDGFRBKITPDGFRA | |
| SCHEMBL7489863 | 0.82 | PDGFRA (0.82) | FGFR2KDRPDGFRA | |
| SCHEMBL5825356 | 0.82 | FGFR2 (0.67) | FGFR2KDRPDGFRBKITPDGFRA | |
| SCHEMBL13936606 | 0.81 | FGFR2 (0.79) | FGFR2KDRPDGFRBKITPDGFRA | |
| SCHEMBL5825531 | 0.81 | FGFR2 (0.73) | FGFR2KDRPDGFRBKITPDGFRA | |
| SCHEMBL4476232 | 0.81 | FGFR2 (0.82) | FGFR2KDRPDGFRBKITPDGFRA | |
| SCHEMBL4465199 | 0.81 | FGFR2 (0.82) | FGFR2KDRPDGFRBKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | FGFR2 1286/4885KDR 2923/4885PDGFRB 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.